Heterogeneity in Infection Reporting Across Covalent Bruton Tyrosine Kinase Inhibitor Studies in B-Cell Malignancies: A Systematic Review
Journal of Hematology · 2026-10 · 15 (5) · 219-224
DOI: 10.14740/jh2233 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Hematology, 2026-10. Verfasst von Musa Kiyani und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kiyani, M., Clanahan, O., & Silverman, M. A. (2026). Heterogeneity in Infection Reporting Across Covalent Bruton Tyrosine Kinase Inhibitor Studies in B-Cell Malignancies: A Systematic Review. Journal of Hematology, 15(5), 219-224. https://doi.org/10.14740/jh2233
Vancouver
Kiyani M, Clanahan O, Silverman MA. Heterogeneity in Infection Reporting Across Covalent Bruton Tyrosine Kinase Inhibitor Studies in B-Cell Malignancies: A Systematic Review. Journal of Hematology. 2026;15(5):219-224. doi:10.14740/jh2233
BibTeX
@article{Kiyani2026,
author = {Kiyani, Musa and Clanahan, Owen and Silverman, Michael A.},
title = {Heterogeneity in Infection Reporting Across Covalent Bruton Tyrosine Kinase Inhibitor Studies in B-Cell Malignancies: A Systematic Review},
journal = {Journal of Hematology},
year = {2026},
volume = {15},
number = {5},
pages = {219--224},
doi = {10.14740/jh2233}
}
EUVIMED